

DOCKET No.: 5865-0009.31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

G.A. Amstutz, et al.

SERIAL No.: 08/496,847

FILED: June 27, 1995

FOR: METHODS AND FORMULATIONS FOR
PREVENTING PROGRESSION OF
NEUROPATHIC PAIN

EXAMINER: Davenport

ART UNIT: 1811

RECEIVED

FEB 20 1998

MATRIX CUSTOMER
SERVICE CENTER

Information Disclosure Statement Submitted
Before Mailing Date of Either a Final Action or Notice
of Allowance (37 CFR § 1.97)

Assistant Commissioner for Patents
Washington, D.C. 20231

MAR - 2 1998

Sir:

Publishing Division
Corres/Allowed Files (02)

1. The information transmitted herewith is being filed after three months of the filing date of this application or after the mailing date of the first Office action on the merits, whichever event occurred last, but before the mailing date of either a final action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, whichever occurs first.
2. Applicant elects to pay the fee set forth in 37 CFR § 1.17(p) [\$240.00] for consideration of this Information Disclosure Statement.
3. ☐ Attached is a check which includes the amount of \$240.00.
☒ Please charge Deposit Account No. _____ in the amount of \$____; a duplicate of this request is attached.
☒ If any additional fees are due, please charge to Deposit Account 04-0531; a duplicate of this request is attached.
4. The references listed on the enclosed Form PTO-1449 (Modified) may be material to the examination of the above-identified application. Copies of the references are submitted herewith. The Examiner is requested to make these references of official record in the application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the

examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Accordingly, it is requested that the Examiner consider the within Form PTO-1449 and cited art.

Respectfully submitted,



Carol A. Stratford
Registration No. 34,444

Date: Feb 19, 1998

Correspondence Address:

Dehlinger & Associates, LLP
P.O. Box 60850
Palo Alto, CA 94306
Phone: (650) 324-0880

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.

5865-0009.31

SERIAL NO.

08/496,847

APPLICANT

Amstutz, G.A., et al.

FILING DATE

06/27/95

GROUP

1811

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,051,403	09/24/91	Miljanich et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	3926287 A1	02/21/91	DE				
	WO 91/07980	06/13/91	PCT				
	WO 93/10145	05/27/93	PCT				
	WO 93/13128	07/08/93	PCT				
	WO 95/01436	01/12/95	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	Bernards, C.M., "Effect of (Hydroxypropyl)- β -cyclodextrin on Flux of Morphine, Fentanyl, Sufentanil, and Alfentanil Through the Spinal Meninges of Monkey," <i>Journal of Pharmaceutical Sciences</i> , <u>83</u> (5):620-622 (1994).
	Bernards, C.M. and Hill, H.F., "Physical and Chemical Properties of Drug Molecules Governing Their Diffusion Through the Spinal Meninges," <i>Anesthesiology</i> , <u>77</u> (4):750-756 (1992).
	Davar, G. et al., "MK-801 Blocks the Development of Thermal Hyperalgesia in a Rat Model of Experimental Painful Neuropathy," <i>Brain Research</i> , <u>553</u> :327-330 (1991).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Dialog Information Services, File 351, WPIL Dialog Accession No. 010083868, WPI Accession No. 94-351581/44, Bristol-Myers Squibb Co: "Stabilised Injection Prepn - Comprises Deoxythymidine Nucleoside and Stabiliser(s) Selected from Sugar Alcohol, Benzyl Alcohol, Phenol, etc"; & JP, A, 6247879, 940906, 9444 (Basic).

Xiao, W.-H. and Bennett, G.J., "Inhibition of Neuropathic Pain By N-type Calcium Channel Blockade with Omega-conopeptides Applied to the Site of Nerve Injury," *Society for Neuroscience Abstracts*, 20:559 (1994).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.